List view / Grid view
3 November 2014 | By Auspherix Pty Ltd
Auspherix Pty Ltd, an early stage anti-infectives company developing novel antibiotics to treat resistant bacterial disease has secured a further with AU$1 million in a series A financing from Australia’s Medical Research Commercialisation Fund (MRCF), to progress its antibacterial compounds through development studies...
3 November 2014 | By Birken
Birken AG, a biopharmaceutical and dermo-cosmetic company, announces that the European Medicines Agency has accepted its Oleogel-S10 Marketing Authorization Application for review...
3 November 2014 | By BioOutsource Ltd
BioOutsource Ltd. announced a major initiative in new research and development programs to support the next generation of biosimilars...
3 November 2014 | By Almirall
Almirall announced that, effective November 1st, it has completed the transaction to transfer to AstraZeneca the rights of Almirall’s respiratory franchise after all closing conditions have been satisfied...
31 October 2014 | By Bristol-Myers Squibb
ZymoGenetics is among an elite group of laboratories around the world that have earned the U.S. Green Building Council’s LEED® (Leadership in Energy and Environmental Design) Silver certification for Existing Buildings: Operations and Maintenance...
31 October 2014 | By Actinogen Ltd
Actinogen Ltd, an Australian biotechnology company, has acquired Edinburgh BioQuarter spin-out, Corticrine Ltd in a deal facilitated and introduced by Professor Alan Boyd of Boyds...
Bristol-Myers Squibb Company and Lonza today announced a multi-year expansion of their existing biologics manufacturing agreement. The contract expansion will include the production of commercial quantities of a second Bristol-Myers Squibb biologic medicine at Lonza’s mammalian manufacturing facility in Portsmouth, New Hampshire. Financial terms were not disclosed.
31 October 2014 | By GlobalData
While the collaboration between Sanofi Pasteur (Sanofi) and Immune Design to develop a genital herpes vaccine presents a strong scientific foundation and difficult-to-match financial clout, the partnership needs to create a product with better clinical performance to compete with more advanced pipeline vaccine candidates, says an analyst with research and…
30 October 2014 | By Bristol-Myers Squibb
Phase 2 objective response rate and survival data for Opdivo (nivolumab) in heavily pre-treated advanced squamous cell non-small cell lung cancer to be presented at the 2014 Chicago Multidisciplinary Symposium on Thoracic Oncology...
Auditing will be a key theme of the British Generic Manufacturers Association’s (BGMA) next BGMA Quality Forum meeting on Wednesday, November 12th which is run in partnership with the MHRA.
30 October 2014 | By Eli Lilly and Company
Eli Lilly and Company published details of its long-standing technology transfer program to increase the global supply of medicines for multidrug-resistant tuberculosis (MDR-TB)...
30 October 2014 | By PresseBox
It has become a tradition to recognize pharma innovation at CPhI Worldwide, as CPhI Pharma awards winners driving Pharma's biggest innovations...
29 October 2014 | By Merck
Merck announced today the signature of a memorandum of understanding with Kenya Medical Research Institution (KEMRI) for a scientific partnership aimed at contributing to the country’s social and economic development. The partnership will cover research and development projects, programs and activities focused on malaria and schistosomiasis, as well as related…
29 October 2014 | By GBI Research
The global Non-Hodgkin Lymphoma (NHL) treatment market will increase in value from $5.6 billion in 2013 to $9.2 billion by 2020, representing a Compound Annual Growth Rate (CAGR) of 7.4%, says business intelligence provider GBI Research...
29 October 2014 | By Eli Lilly and Company
Eli Lilly and Company (LLY) will participate in the Credit Suisse 2014 Healthcare Conference at the Arizona Biltmore in Phoenix, AZ, on Wednesday, November 12, 2014. Jeffrey Simmons, Senior Vice President and President, Elanco Animal Health, will make a formal presentation at 1:30 p.m. EST...
